Mesothelioma

Stage 2 Mesothelioma News

Oncolytics Biotech Inc. Announces 2008 Second Quarter ResultsTuesday, July 29, 2008 @ 8:14PM Oncolytics Biotech Inc. today announced its financial results and highlights for the three and six month periods ended June 30, 2008.

JapanToday : Japan News and Discussion ジャパントゥデイ:日本のニュースを英語で読むMonday, July 14, 2008 @ 8:47PMWhen one thinks of Oji Paper, Japan’s largest paper manufacturing company (in terms of consolidated sales), the image is of vast green forests in Hokkaido, excellent paper-making technology, and the guiding hand of Eichi Shibusawa.

JapanToday : Japan News and Discussion ジャパントゥデイ:日本のニュースを英語で読むMonday, July 14, 2008 @ 8:47PMWhen one thinks of Oji Paper, Japan’s largest paper manufacturing company (in terms of consolidated sales), the image is of vast green forests in Hokkaido, excellent paper-making technology, and the guiding hand of Eichi Shibusawa.

JapanToday : Japan News and Discussion ジャパントゥデイ:日本のニュースを英語で読むMonday, July 14, 2008 @ 8:47PMWhen one thinks of Oji Paper, Japan’s largest paper manufacturing company (in terms of consolidated sales), the image is of vast green forests in Hokkaido, excellent paper-making technology, and the guiding hand of Eichi Shibusawa.

JapanToday : Japan News and Discussion ジャパントゥデイ:日本のニュースを英語で読むMonday, July 14, 2008 @ 8:47PMWhen one thinks of Oji Paper, Japan’s largest paper manufacturing company (in terms of consolidated sales), the image is of vast green forests in Hokkaido, excellent paper-making technology, and the guiding hand of Eichi Shibusawa.

JapanToday: Japan News and Discussion ジャパントゥデイ:日本のニュースを英語で読むMonday, July 14, 2008 @ 8:47PMWhen one thinks of Oji Paper, Japan’s largest paper manufacturing company (in terms of consolidated sales), the image is of vast green forests in Hokkaido, excellent paper-making technology, and the guiding hand of Eichi Shibusawa.

Alfacell Updates Status of ONCONASE(R) Phase III Clinical ProgramWednesday, April 2, 2008 @ 8:30AM Alfacell Corporation today announced that it has confirmed that 316 evaluable events have occurred in the confirmatory Phase IIIb clinical trial of its lead compound, ONCONASE , for the treatment of patients with unresectable malignant mesothelioma .

Staff WriterTuesday, January 15, 2008 @ 8:48PMAlfacell Corp. licensed U.S. commercialization rights for the Phase III cancer drug Onconase (ranpirnase) to Strativa Pharmaceuticals in a deal worth up to $225 million.